NUCRYST Pharmaceuticals Corp. (USA) (NASDAQ:NCST)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $1.75 |
| Daily Range | $1.77 - $1.77 |
| 52-Week Range | $0.25 - $1.79 |
| Market Cap | $32.44M |
| P/E Ratio | 175.20 |
| Dividend (Yield) | 0.80 (45.20%) |
| Volume | 0 |
| Average Daily Volume | 0 |
NCST
VS S&P 500 (SPY)
This ticker is not currently Ratable.
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
NCST Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
NCST News and Commentary
- Cashing In on Obamacare – The Motley Fool
Related News and Articles
- Are These Medical Companies Cash Kings? – The Motley Fool
- Has Medtronic Become the Perfect Stock? – The Motley Fool
- Does Boston Scientific Pass Buffett's Test? – The Motley Fool
- Wall Street Just Doesn't Understand This Stock – The Motley Fool
- 1 Great Dividend You Can Buy Right Now – The Motley Fool
- Can This Moat Still Stave Off Invading Hordes? – The Motley Fool
- Are These 2 Medical Device Makers Takeover Targets? – The Motley Fool
- Has St. Jude Medical Become the Perfect Stock? – The Motley Fool
- Has Intuitive Surgical Become the Perfect Stock? – The Motley Fool
- 18 More Reasons to Love This Rule Breaker – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Can Varian's Stock Be Cheap by the Numbers? – The Motley Fool
- 5-Star Stocks Poised to Pop: Stryker – The Motley Fool
- CR Bard Passes This Key Test – The Motley Fool
- Why Medtronic Is On Course for a Happy New Year – The Motley Fool
- I'm Buying This Stock Right Now – The Motley Fool
- 4-Star Stocks Poised to Pop: Accuray – The Motley Fool
RSS Headlines
Fool UK
